Inhaled nitric oxide selectively dilates pulmonary vasculature in adult patients with pulmonary hypertension, irrespective of etiology. (Q54025987)

23 May 2018

title

Inhaled nitric oxide selectively dilates pulmonary vasculature in adult patients with pulmonary hypertension, irrespective of etiology. (English)

1 reference

23 May 2018

main subject

arterial hypertension

0 references

pulmonary hypertension

1 reference

1

1 reference

23 May 2018

author name string

Warner JJ

2

1 reference

23 May 2018

Wang A

3

1 reference

23 May 2018

Harrison JK

4

1 reference

23 May 2018

Tapson VF

5

1 reference

23 May 2018

Bashore TM

6

1 reference

23 May 2018

language of work or name

English

0 references

publication date

1 December 2000

1 reference

23 May 2018

Journal of the American College of Cardiology

published in

1 reference

23 May 2018

volume

36

1 reference

23 May 2018

issue

7

1 reference

23 May 2018

page(s)

2204-2211

1 reference

23 May 2018

Primary pulmonary hypertension

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900994-3

7 January 2021

The management of primary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900994-3

7 January 2021

A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900994-3

7 January 2021

The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900994-3

7 January 2021

Nitric oxide regulates basal systemic and pulmonary vascular resistance in healthy humans

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900994-3

7 January 2021

Chronic cor pulmonale. Etiology and management

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900994-3

7 January 2021

Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Nocturnal Oxygen Therapy Trial Group

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900994-3

7 January 2021

Combination of inhaled nitric oxide with i.v. nitroglycerin or with a prostacyclin analogue in the treatment of experimental pulmonary hypertension.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900994-3

7 January 2021

Effects of inhaled nitric oxide in rats with chemically induced pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900994-3

7 January 2021

Low-dose inhaled nitric oxide for neonates with pulmonary hypertension.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900994-3

7 January 2021

Inhaled nitric oxide in infants referred for extracorporeal membrane oxygenation: dose response

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900994-3

7 January 2021

Nitric oxide, oxygen, and prostacyclin in children with pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900994-3

7 January 2021

Primary pulmonary hypertension. A national prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900994-3

7 January 2021

Delivery and monitoring of inhaled nitric oxide in patients with pulmonary hypertension.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900994-3

7 January 2021

Combined effects of nitric oxide and oxygen during acute pulmonary vasodilator testing.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900994-3

7 January 2021

The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900994-3

7 January 2021

Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900994-3

7 January 2021

The use of inhaled nitric oxide in a wide variety of clinical problems

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900994-3

7 January 2021

Effects of endothelium-derived nitric oxide on peripheral arteriolar tone in man

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900994-3

7 January 2021

Role of endothelium-derived nitric oxide in the regulation of blood pressure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900994-3

7 January 2021

Pulmonary vasoconstriction and hypertension in mice with targeted disruption of the endothelial nitric oxide synthase (NOS 3) gene

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900994-3

7 January 2021

Chronic nitric oxide inhibition in utero produces persistent pulmonary hypertension in newborn lambs

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900994-3

7 January 2021

Inhaled nitric oxide as a cause of selective pulmonary vasodilatation in pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900994-3

7 January 2021

Long-term inhalation of nitric oxide for a patient with primary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900994-3

7 January 2021

Clinical responses to prolonged treatment of persistent pulmonary hypertension of the newborn with low doses of inhaled nitric oxide

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900994-3

7 January 2021

Effect of inhaled nitric oxide on gas exchange in patients with congestive heart failure. A randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900994-3

7 January 2021

Cardiovascular effects of inhaled nitric oxide in patients with left ventricular dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900994-3

7 January 2021

The effect of low-dose inhalation of nitric oxide in patients with pulmonary fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900994-3

7 January 2021

Acute hemodynamic responses to inhaled nitric oxide in patients with limited scleroderma and isolated pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900994-3

7 January 2021

Effect of inhaled nitric oxide on hemodynamics and VA/Q inequalities in patients with chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900994-3

7 January 2021

Inhaled nitric oxide in chronic obstructive lung disease

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900994-3

7 January 2021

Inhaled nitric oxide for the adult respiratory distress syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900994-3

7 January 2021

Prolonged inhalation of low concentrations of nitric oxide in patients with severe adult respiratory distress syndrome. Effects on pulmonary hemodynamics and oxygenation.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900994-3

7 January 2021

Inhaled nitric oxide in congenital heart disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900994-3

7 January 2021

Nitric oxide and pulmonary hypertension.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900994-3

7 January 2021

Long-term therapy for pulmonary hypertension in children.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900994-3

7 January 2021

Pulsed delivery of inhaled nitric oxide to patients with primary pulmonary hypertension: an ambulatory delivery system and initial clinical tests

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900994-3

7 January 2021

Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900994-3

7 January 2021

Inhaled nitric oxide in primary pulmonary hypertension: a safe and effective agent for predicting response to nifedipine

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900994-3

7 January 2021

Nitric oxide in adult lung disease

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900994-3

7 January 2021

Inhaled nitric oxide as a screening vasodilator agent in primary pulmonary hypertension. A dose-response study and comparison with prostacyclin.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900994-3

7 January 2021

Role of vasoactive mediators in primary and secondary pulmonary hypertension.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900994-3

7 January 2021

Improvement in pulmonary hypertension and hypoxemia during nitric oxide inhalation in a patient with end-stage pulmonary fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900994-3

7 January 2021

The medical treatment of primary pulmonary hypertension. Proven and promising strategies

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900994-3

7 January 2021

Compassionate use of continuous prostacyclin in the management of secondary pulmonary hypertension: a case series

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900994-3

7 January 2021

Nebulized prostacyclin for pulmonary hypertension: a step in the right direction

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900994-3

7 January 2021

An evaluation of nebulized prostacyclin in patients with primary and secondary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900994-3

7 January 2021

Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900994-3

7 January 2021

Long-term effects of nitrendipine on hemodynamics and oxygen transport in patients with cor pulmonale.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900994-3

7 January 2021

Felodipine improves pulmonary hemodynamics in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900994-3

7 January 2021

Prognostic factors in COPD patients receiving long-term oxygen therapy. Importance of pulmonary artery pressure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900994-3

7 January 2021

The effect of the calcium antagonist, isradipine, on working capacity, pulmonary function, morbidity and survival rate in patients with severe chronic obstructive pulmonary disease (COPD): a randomized, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900994-3

7 January 2021

10.1016/S0735-1097(00)00994-3

Identifiers

DOI

1 reference

23 May 2018

PubMed ID

11127462

1 reference

23 May 2018